|
PSCI-19-109 |
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE) |
|
PSCI-20-009 |
Effect of oral black raspberry administration on oral cell DNA adducts in smokers |
|
PSCI-20-013 |
Difference in care and trends in outcomes of adolescent and young adult AML patients treated in pediatric and adult centers |
|
PSCI-20-016 |
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA |
|
PSCI-20-020 |
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE) |
|
PSCI-20-022 |
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355) |
|
PSCI-20-023 |
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy |
|
PSCI-20-025 |
A Multi-Institutional Retrospective Study of Patient Characteristics, Treatment Patterns and Outcomes in Older Patients with Primary Central Nervous System Lymphoma |
|
PSCI-20-035 |
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma |
|
PSCI-20-036 |
The COVID-19 and Cancer Consortium (CCC19) Registry |
